title: [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
authors.forename: Toshirou
authors.initials: T
authors.lastname: Nishida
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Tsukazaki
mesh_terms: D001549:Benzamides / Q000009:adverse effects* / Q000627:therapeutic use; D000069439:Dasatinib; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D016374:Oncogene Proteins v-abl / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D016374:Oncogene Proteins v-abl; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor; C498826:nilotinib; D000069439:Dasatinib